Calidi Biotherapeutics Inc

Research Calidi Biotherapeutics Inc (CLDI) on Bullrun: market cap USD 3.11M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCLDI
• ExchangeNYSE MKT
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 3.11M
• Financial periodFY2025
• Net income-USD 19.91M

Valuation Snapshot

latest market cap is USD 3.11M.

About Calidi Biotherapeutics Inc

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease. The company offers CLD-101, which is in Phase 1b/2 clinical trial for the treatment of newly diagnosed high grade glioma, as well as in Phase 1 dose-escalation clinical trial for recurrent high-grade glioma; CLD-201 product for solid tumors, such as breast cancer, head and neck cancer, and sarcoma; and CLD-401 for the treatment of metastatic solid tumors.

Frequently asked questions

What is Calidi Biotherapeutics Inc's market cap?

Calidi Biotherapeutics Inc's market capitalization is USD 3.11M.

What does Calidi Biotherapeutics Inc do?

Calidi Biotherapeutics, Inc., a biotechnology company, develops targeted therapies to deliver genetic medicines to distal sites of disease.